Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Jeffrey Leiden purchased 5,000 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were purchased at an average price of $20.00 per share, with a total value of $100,000.00. Following the completion of the acquisition, the director directly owned 270,198 shares of the company’s stock, valued at approximately $5,403,960. This trade represents a 1.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Odyssey Therapeutics Price Performance
Odyssey Therapeutics stock opened at $17.45 on Tuesday. Odyssey Therapeutics, Inc. has a 52 week low of $15.35 and a 52 week high of $20.30.
Featured Articles
- Five stocks we like better than Odyssey Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
